Anatomy and Cell Biology, University of Marburg, Robert-Koch-Str. 8, Marburg, Germany.
Curr Mol Med. 2010 Mar;10(2):180-205. doi: 10.2174/156652410790963330.
Motivated by the challenge of risk assessment in a heterogeneous population and guided by advances in our knowledge of the pathobiology of cardiovascular diseases (CVD), basic and clinical scientists have maintained substantial interest in the development and application of novel biomarkers for risk stratification of CVD. In particular, strategies to identify and combine multiple biomarkers, which may reflect diverse pathobiological contributors to the onset and complications of CVD, have been arising as an approach to improve more effectively the risk assessment and target therapy. Moreover, comparative evaluations of novel markers are necessary to estimate these candidates for integration into present and future strategies. In this review we consider the recent in-depth knowledge and advances with the use of systemic biomarkers in the area of CVD with special attention on inflammatory markers and those that can predict an individual arteriosclerotic disease stage.
受异质人群风险评估挑战的推动，并以心血管疾病（CVD）病理生物学知识的进步为指导，基础和临床科学家对开发和应用新型 CVD 风险分层生物标志物保持了浓厚的兴趣。特别是，为了更有效地改善风险评估和靶向治疗，已经出现了识别和结合多种生物标志物的策略，这些生物标志物可能反映了 CVD 发病和并发症的多种病理生物学因素。此外，需要对新型标志物进行比较评估，以估计这些候选标志物是否可整合到现有和未来的策略中。在这篇综述中，我们考虑了最近在 CVD 领域使用系统性生物标志物方面的深入知识和进展，特别关注炎症标志物和那些可以预测个体动脉粥样硬化疾病阶段的标志物。
